companiesCompany
Hansoh Pharmaceutical Group
aka Hansoh, 翰森制药
Hansoh makes aumolertinib, China's most prescribed third-generation EGFR lung cancer pill, and has licensed two ADCs to GSK.
Overview
Aumolertinib (Ameile) approved 2020 and first line 2021; the BTK inhibitor and CNS-focused pipeline; and B7-H4 (HS-20089) and B7-H3 (HS-20093) ADCs licensed to GSK in 2023 for $85 million and $185 million upfront. Also the GLP-1 agreements with Merck & Co. outside oncology. Run by Zhong Huijuan, one of the world's wealthiest self-made women.
Headquarters
Lianyungang / Shanghai, CN
Scorecard
All companies#97of 680 companies, score 27
- approved products +6
- targets +2
- modalities +2
- regions +2
- registry trials +15
1 approved, 0 in phase 3, 0 earlier, 1 targets, 59 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2023-10-20 | Hansoh Pharmaceutical Group to GSK HS-20089 (GSK5733584), B7-H4 ADC | Licence | $85m | up to $1.485bn | source |
Type
pharma · 3692.HK
Stage
Public
Website
Founded
1995
Pages like this
not linked directly; found by shared links- CompanySino Biopharmaceutical (Chia Tai Tianqing)
Shares Merck & Co. (MSD) and the tag china.
- TrialFURLONG
Shares AENEAS and the tag china.
- CompanyZai Lab
Shares GSK and the tag china.